NCT07196163View on ClinicalTrials.gov

An Exploratory Study of Golidocitinib in Adult Patients With ITP

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

October 30, 2025

Primary Completion Date

October 30, 2028

Study Completion Date

October 30, 2029

Conditions
Immune Thrombocytopenia (ITP)
Interventions
DRUG

Golidocitinib

Golidocitinib will be administered orally as capsules in a 28-day cycle.

DRUG

Placebo

Placebo will be administered orally as capsules in a 28-day cycle.

Trial Locations (1)

100010

Peking University Insititute of Hematology, Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER

NCT07196163 - An Exploratory Study of Golidocitinib in Adult Patients With ITP | Biotech Hunter | Biotech Hunter